MALVERN, Pa., Aug 19 (Bernama-BUSINESS WIRE) — DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry along with their CRO partner, Bestat Pharmaservices Corp. (Bestat) are building studies to support COVID-19 treatments and vaccines in Asia. This includes a study now progressing to Phase III that evaluates a novel monoclonal antibody as a treatment to neutralize SARS-CoV-2 by binding to specific proteins found on the surface of the virus.
With the medical community facing extraordinary challenges, as it desperately searches for a vaccine to slow the progression and accelerate recovery of SARS-CoV-2, it is critical to have the ability to build effective clinical trial solutions at a rapid pace and also be adaptive to the ever changing landscape and challenges brought on by the pandemic. DSG, with its proven and intuitive eCaseLink platform provides the right tools for Bestat to achieve these goals.